Sarsasapogenin ameliorates diabetes‐associated memory impairment and neuroinflammation through down‐regulation of PAR‐1 receptor

• Published in: Phytotherapy research Vol. 35; no. 6; pp. 3167 - 3180
• Main Authors: Kong, Li, Liu, Yue, Zhang, Yu‐Meng, Li, Yu, Gou, Ling‐Shan, Ma, Teng‐Fei, Liu, Yao‐Wu
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01.06.2021; Wiley Subscription Services, Inc
• Subjects: advanced glycation end products; Advanced glycosylation end products; antagonists; Cerebral cortex; Cognition; Cognitive ability; cognitive disorders; Diabetes; Diabetes mellitus; diabetes‐associated cognitive impairment; Glucose; hippocampus; Impairment; Inflammasomes; Inflammation; Leucine; Memory; memory disorders; neuroinflammation; neurons; Neuroprotection; neuroprotective effect; NF‐κB; Nucleotides; phytotherapy; protease‐activated receptor 1; Receptors; Rodents; Sarsasapogenin; Streptozocin; the NLRP1 inflammasome; Thrombin; NF-κB; the NLRP1 inflammasome; protease-activated receptor 1; diabetes-associated cognitive impairment; neuroinflammation; sarsasapogenin

Sarsasapogenin (Sar), a natural steroidal compound, shows neuroprotection, cognition‐enhancement, antiinflammation, antithrombosis effects, and so on. However, whether Sar has ameliorative effects on diabetes‐associated cognitive impairment remains unknown. In this study, we found that Sar ameliorat...